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Background
The HIV-1 viral infectivity factor (VIF) binds to the host
defense factor human APOBEC3G (hA3G) and prevents
its assembly with viral particles and mediates its elimina-
tion. VIF binds Elongin B/C complex of the ubiquitina-
tion machinery and it also forms multimers. Knowledge
of the surface accessibility by solvents and other proteins
and antigenicity is important in designing B and T cell
epitopes that could be used as antiretroviral drugs and
vaccine to block the activity of Vif. Inactivation of Vif sup-
ports the role of hA3G in inhibiting in vivo replication of
the virus.
Methods
The VIF protein sequence was downloaded from NCBI
database and blast search was performed against Uniprot
and Swissprot databases to get a protein sequence with
high expected value (e-value). The protein was analyzed
for the following surface properties; Emini surface accessi-
bility by solvents and other proteins, Kolaskar antigenicity
and B and T cell epitopes for 42 MHC class I alleles.
Online bioinformatics tools available in immuneepitope.
org database were used.
Results
VIF protein sequence with e-value of 1e-114 was found to
be the best. Four peptides two of nine and the rest 11 and
19 amino acids were shown to have good Emini surface
accessibility prediction scores. 11 peptides were found to
be antigenic with two of these having the SOCS homology
box (SLQYLAL) and the dimerization box (PPLP). 18 T
cell epitopes had significant binding to MHC class 1 alle-
les with IC50 < 20. Top three epitopes had dimerization
domain and IC50 value < 5.2. The rest had both dimeriza-
tion and SOCS homology box residues.
Conclusion
A synthetic peptide with Vif specific amino acids of these
sites could induce anti-Vif neutralizing antibodies and
stimulate B and T cells. Our In silico analysis suggests that
HIV-1 Vif protein surface features can be used as potential
anti-HIV drug and vaccine target.
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